Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.

2019-nCoV Vaccine mRNA-1273 / immunology Adult Aged Antibodies, Monoclonal / immunology Antibodies, Neutralizing / immunology Antibodies, Viral / immunology Antibody Affinity BNT162 Vaccine / immunology COVID-19 Vaccines / immunology Cohort Studies Cross Reactions Enzyme-Linked Immunosorbent Assay Epitopes, B-Lymphocyte / immunology Evolution, Molecular Female Humans Male Memory B Cells / immunology Middle Aged Neutralization Tests Protein Domains / immunology Spike Glycoprotein, Coronavirus / chemistry Vaccines, Synthetic / immunology Young Adult mRNA Vaccines / immunology

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
12 2021
Historique:
received: 25 07 2021
accepted: 24 09 2021
pubmed: 8 10 2021
medline: 12 1 2022
entrez: 7 10 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern

Identifiants

DOI: 10.1038/s41586-021-04060-7 PMID: 34619745 PMC: PMC8674133
pubmed: 34619745
doi: 10.1038/s41586-021-04060-7
pii: 10.1038/s41586-021-04060-7
pmc: PMC8674133
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Epitopes, B-Lymphocyte 0
Spike Glycoprotein, Coronavirus 0
Vaccines, Synthetic 0
mRNA Vaccines 0
spike protein, SARS-CoV-2 0
2019-nCoV Vaccine mRNA-1273 EPK39PL4R4
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

517-522

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI078788
Pays : United States
Organisme : NIH HHS
ID : 2U19 AI111825
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI064003
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111825
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021).
Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 6, https://doi.org/10.1126/sciimmunol.abi6950 (2021).
Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442 (2020).
doi: 10.1038/s41586-020-2456-9
Apostolidis, S. A. et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Preprint at https://doi.org/10.1101/2021.06.23.21259389 (2021).
Sokal, A. et al. Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals. Preprint at https://doi.org/10.1101/2021.06.17.448459 (2021).
Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021).
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
doi: 10.1038/s41586-021-03207-w
Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).
Pilishvili, T. et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel—33 U.S. sites, January–March 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 753–758 (2021).
doi: 10.15585/mmwr.mm7020e2
Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585–594 (2021).
Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936–3948 (2021).
doi: 10.1016/j.cell.2021.06.005
Reynolds, C. J. et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 372, 1418–1423 (2021).
Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021).
doi: 10.1038/s41586-021-03324-6
Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 372, 1413–1418 (2021).
West, A. P. et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Preprint at https://doi.org/10.1101/2021.02.14.431043 (2021).
Edara, V. V. et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N. Engl. J. Med. 385, 664–666 (2021).
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280(2021).
Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 30, 429–457 (2012).
doi: 10.1146/annurev-immunol-020711-075032
Dugan, H. L. et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54, 1290–1303 (2021).
doi: 10.1016/j.immuni.2021.05.001
Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219 (2021).
doi: 10.1016/j.cell.2021.06.021
Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643–650 (2020).
doi: 10.1126/science.abc5902
Kreer, C. et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 182, 843–854 (2020).
doi: 10.1016/j.cell.2020.06.044
Seydoux, E. et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity 53, 98–105 (2020).
doi: 10.1016/j.immuni.2020.06.001
Taylor, J. J., Pape, K. A., Steach, H. R. & Jenkins, M. K. Apoptosis and antigen affinity limit effector cell differentiation of a single naive B cell. Science 347, 784–787 (2015).
doi: 10.1126/science.aaa1342
Muecksch, F. et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853–1868 (2021).
doi: 10.1016/j.immuni.2021.07.008
Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047–9052 (2012).
doi: 10.1073/pnas.1118979109
Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667–671 (2008).
doi: 10.1038/nature06890
Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007).
doi: 10.1056/NEJMoa066092
Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19
doi: 10.1016/j.immuni.2015.06.016
Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, https://doi.org/10.1126/science.abf4063 (2021).
Sakharkar, M. et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci. Immunol. 6, https://doi.org/10.1126/sciimmunol.abg6916 (2021).
Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80–82 (2021).
doi: 10.1056/NEJMc2032195
Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227–1230 (2020).
doi: 10.1126/science.abd7728
Pegu, A. et al. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. Preprint at https://doi.org/10.1101/2021.05.13.444010 (2021).
Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021).
doi: 10.1038/s41591-021-01294-w
Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187–189 (2021).
doi: 10.1056/NEJMc2104974
Hacisuleyman, E. et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N. Engl. J. Med. 384, 2212–2218 (2021).
doi: 10.1056/NEJMoa2105000
Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533–540 (2021).
doi: 10.1056/NEJMoa2034545
Gazit, S. et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. Preprint at https://doi.org/10.1101/2021.08.24.21262415 (2021).
Mesin, L. et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell 180, 92–106 (2020).
doi: 10.1016/j.cell.2019.11.032
Pape, K. A., Taylor, J. J., Maul, R. W., Gearhart, P. J. & Jenkins, M. K. Different B cell populations mediate early and late memory during an endogenous immune response. Science 331, 1203–1207 (2011).
doi: 10.1126/science.1201730
Viant, C. et al. Antibody affinity shapes the choice between memory and germinal center B cell fates. Cell 183, 1298–1311 (2020).
doi: 10.1016/j.cell.2020.09.063
Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201–1213 (2021).
doi: 10.1016/j.cell.2021.01.050
Feng, L. et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques. Nat. Commun. 11, 4207 (2020).
doi: 10.1038/s41467-020-18077-5
Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169–184 (2020).
doi: 10.1016/j.cell.2020.08.026
Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl. Med. 13, https://doi.org/10.1126/scitranslmed.abi9915 (2021).
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217, 345–351 (2015).
doi: 10.1016/j.jconrel.2015.08.007
Wu, K. et al. Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster. Preprint at https://doi.org/10.1101/2021.05.05.21256716 (2021).
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
doi: 10.1038/s41591-021-01377-8
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
doi: 10.1038/s41586-020-2008-3
Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).
doi: 10.1038/s41591-020-0913-5
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501 (2020).
doi: 10.1016/j.cell.2020.05.015
Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828–842 (2020).
doi: 10.1016/j.cell.2020.06.025
Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020).
Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, https://doi.org/10.1126/scitranslmed.abf1555 (2021).
Gupta, N. T. et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics 31, 3356-3358 (2015).
doi: 10.1093/bioinformatics/btv359
Soto, C. et al. High frequency of shared clonotypes in human B cell receptor repertoires. Nature 566, 398–402 (2019).
doi: 10.1038/s41586-019-0934-8
Guo, Y., Chen, K., Kwong, P. D., Shapiro, L. & Sheng, Z. cAb-Rep: a database of curated antibody repertoires for exploring antibody diversity and predicting antibody prevalence. Front. Immunol. 10, 2365 (2019).
doi: 10.3389/fimmu.2019.02365

Auteurs

Alice Cho (A)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0001-6354-6148

Frauke Muecksch (F)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0002-0132-5101

Dennis Schaefer-Babajew (D)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0002-5380-2950

Zijun Wang (Z)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Shlomo Finkin (S)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0003-4474-2658

Christian Gaebler (C)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0001-7295-8128

Victor Ramos (V)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0001-7353-3420

Melissa Cipolla (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Pilar Mendoza (P)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Marianna Agudelo (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Eva Bednarski (E)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0003-4438-5590

Justin DaSilva (J)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0001-6393-0000

Irina Shimeliovich (I)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Juan Dizon (J)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Mridushi Daga (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Katrina G Millard (KG)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0003-2247-3178

Martina Turroja (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0001-9640-0559

Fabian Schmidt (F)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.

Fengwen Zhang (F)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.

Tarek Ben Tanfous (TB)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Mila Jankovic (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Thiago Y Oliveria (TY)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0002-2654-0879

Anna Gazumyan (A)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Marina Caskey (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.
ORCID: 0000-0003-1727-8693

Paul D Bieniasz (PD)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
Howard Hughes Medical Institute, New York, NY, USA. pbieniasz@rockefeller.edu.
ORCID: 0000-0002-2368-3719

Theodora Hatziioannou (T)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.
ORCID: 0000-0002-7889-0766

Michel C Nussenzweig (MC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.
Howard Hughes Medical Institute, New York, NY, USA. nussen@rockefeller.edu.
ORCID: 0000-0003-0592-8564

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin ARNm-1273 contre la COVID-19 › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Affinité des anticorps › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Réactions croisées › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Dosage immunologique › Techniques d'immunoadsorption › Test ELISA › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Déterminants antigéniques des lymphocytes B › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Phénomènes biologiques › Évolution biologique › Évolution moléculaire › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Sous-populations de lymphocytes B › Cellules B mémoire › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Tests de neutralisation › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Anti-SARS-CoV-2 receptor-binding domain...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Anti-SARS-CoV-2 receptor-binding domain...